Back to Atlas
CTransientStandard research/education caution
CMP-0327
Approved drug; longevity use investigational
Everolimus
Senomorphic / mTOR
Senescence-program suppression and geroprotective positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Rapalog
- Primary mechanism
- mTORC1 inhibition suppresses growth/SASP signaling
- Primary market use
- Immunology / oncology / longevity
Pharmacology
- Molecular weight (Da)
- 958.2
- Oral bioavailability
- Oral; ~30%
- Half-life
- ~30 h
- Route tags
- Route-dependent / verify
- Evidence level
- Approved/Human
- Clinical status
- Approved drug; longevity use investigational
- Value-for-money score
- 4 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Rapalog with plausible senomorphic effects but immunosuppression and cost reduce value